Currently Viewing:
Newsroom
Currently Reading
A First: FDA Approves Pembrolizumab for Tissue-Agnostic Indication
May 23, 2017 – Surabhi Dangi-Garimella, PhD
Multigene Testing Can Inform Predisposition to Inherited Prostate Cancer
May 22, 2017 – Surabhi Dangi-Garimella, PhD
Report Outlines Burden of Rare Cancers, Including Poorer Survival Rates
May 22, 2017 – Christina Mattina
What We're Reading: E-Cigarette Rule Delay; Metformin Safety; "Fittest City" Rankings
May 22, 2017 – AJMC Staff
Study Identifies Patterns of Peer Pressure With Advanced Imaging in Breast Cancer
May 19, 2017 – Surabhi Dangi-Garimella, PhD
Avalere and FasterCures Release Patient-Perspective Value Framework 1.0
May 18, 2017 – Surabhi Dangi-Garimella, PhD
FDA Expands Use of Kalydeco to Treat Cystic Fibrosis Caused by Rare Mutations
May 18, 2017 – Christina Mattina
Tai Chi an Effective Treatment for Insomnia in Breast Cancer Survivors
May 17, 2017 – Christina Mattina
Identifying Promising Targets to Develop Treatments for Rare Diseases
May 17, 2017 – Laura Joszt

A First: FDA Approves Pembrolizumab for Tissue-Agnostic Indication

Surabhi Dangi-Garimella, PhD
The drug is now indicated for adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors that lack suitable alternative treatments or that have progressed on treatment.
Following a review of data from 15 different cancer types, the FDA has granted accelerated approval to the programmed death 1 (PD-1) inhibitor pembrolizumab for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that lack suitable alternative treatments or that have progressed on treatment. The indication also includes patients with colorectal cancer (CRC) that is MSI-H or dMMR and who have progressed on fluoropyrimidine, oxaliplatin, and irinotecan.

The data from 5 uncontrolled, multi-center, single-arm studies, included 149 patients with MSI-H or dMMR cancers—a majority (90) had CRC and the remaining 59 were diagnosed with one of 14 other cancers. Patients were treated with 200 mg pembrolizumab every 3 weeks, or 10 mg/kg every 2 weeks, for a maximum of 24 weeks, until unacceptable toxicity or progression was observed.

The objective response rate was 39.6% (95% CI, 31.7 to 47.9) and the minimum duration of response was 6 months in 78% of patients who responded to the PD-1 inhibitor. Further, 11 complete responses and 48 partial responses were documented.

Merck, which has developed the drug, is expected to conduct further studies to confirm the clinical benefit of pembrolizumab for this indication.   

In the past month, pembrolizumab has received FDA approvals for several indications, including advanced or metastatic urothelial carcinoma and metastatic nonsquamous non-small cell lung cancer (NSCLC). It was one of the first immuno-oncology agents to be approved for melanoma and for non-small cell lung cancer.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up